Abstract
Mice bearing the Eμ-myc transgene, which links the immunoglobulin heavy chain enhancer (Eμ) with c-myc, are predisposed to developing B cell lymphomas. Several B lineage cell lines have been isolated from these animals, and some have been converted to macrophages following infection with v-raf. In this study we compared the regulation of myc expression in Eμ-myc B lymphoma lines, their macrophage counterparts and other non-myc transformed B cell lines. Nuclear run-on analyses demonstrated that transcription of the transgene was elevated in Eμ-myc B cell lines. Moreover, the presence of a 600 bp ΦX174 marker in the 3′ end of the transgene produced a marked stabilisation of this RNA species. Consequently, steady state myc mRNA levels in the Eμ-myc B lymphoma cells were tenfold higher than the macrophage derivatives and non-myc transformed B lineage lines. Despite the considerable difference in myc RNA levels, the Eμ-myc B cell lines contained only 30 – 50% more Myc protein than the other cell lines. This discrepancy between RNA and protein content was not due to increased degradation of the protein as the half life was normal in the transgenic cell lines. These results indicate that both Eμ and ΦX174 sequences influence transgenic myc expression and that protein levels do not correlate with RNA content in Eμ-myc cell lines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colley, S., Tilbrook, P. & Klinken, S. Increased transcription of the Eμ-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein. Oncogene 14, 2735–2739 (1997). https://doi.org/10.1038/sj.onc.1201113
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201113